Traders should monitor the upcoming topline data from the HAELO Phase 3 trial by mid-2026, which could be a significant catalyst. The resolution of the clinical hold for the MAGNITUDE-2 trial is positive, but the ongoing hold on the MAGNITUDE trial for ATTR-CM remains a key risk. The improved financials and cash runway provide near-term stability.
Price Chart
Executive Summary
Intellia Therapeutics reported its Q4 and full-year 2025 financial results, highlighting a reduction in net loss to $95.8 million from $128.9 million in Q4 2024, driven by lower R&D expenses. The company maintains a strong cash position of $605.1 million, sufficient to fund operations into mid-2027. Key clinical developments include advancing its lonvo-z program for HAE with Phase 3 data expected by mid-2026 and resolving the clinical hold for the MAGNITUDE-2 trial of nex-z for ATTRv-PN, while ongoing discussions with the FDA continue regarding the hold on the MAGNITUDE trial for ATTR-CM.
Key Financial Metrics
Key Facts
- Net loss decreased to $95.8 million in Q4 2025 from $128.9 million in Q4 2024.
- Cash, cash equivalents, and marketable securities totaled $605.1 million as of December 31, 2025.
- R&D expenses decreased to $88.7 million in Q4 2025 from $116.9 million in Q4 2024.
- Collaboration revenue increased to $23.0 million in Q4 2025 from $12.9 million in Q4 2024.
- Clinical hold on the MAGNITUDE-2 trial for nex-z in ATTRv-PN was lifted on January 27, 2026.
- FDA engagement is ongoing to resolve the clinical hold on the MAGNITUDE trial for nex-z in ATTR-CM.
- Topline data from the HAELO Phase 3 trial for lonvo-z in HAE is expected by mid-2026.
Financial Impact
Net loss improved by $33.1 million in Q4 2025, with cash burn decreasing due to lower R&D spend. Collaboration revenue increased by $10.1 million YoY.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Collaboration | $23.0M | +78.4% |
Risk Factors
- Ongoing clinical hold on the MAGNITUDE trial for nex-z in ATTR-CM could delay development and impact investor sentiment.
- The success of the lonvo-z program is critical, and any negative data from the HAELO Phase 3 trial could significantly impact the stock.
- The company remains in a pre-revenue stage, dependent on clinical trial outcomes and future funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073456 |
| Document: ntla-20260226.htm | 0001193125-26-073456 |
| Document: 0001193125-26-073456-index-headers.html | 0001193125-26-073456 |
| Document: 0001193125-26-073456-index.html | 0001193125-26-073456 |
| Document: 0001193125-26-073456.txt | 0001193125-26-073456 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.23 (−11.92%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.23 (−8.03%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.23 (−0.09%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.23 (−18.21%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.23 (−22.12%) |
Apr 27, 2026 25w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.23 (+14.92%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.23 (−13.88%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.23 (−15.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers